Boehringer buys Swiss biotech in its lat­est M&A deal, go­ing the next-gen can­cer vac­cine route

Boehringer In­gel­heim has snapped up a Swiss biotech start­up and added their group as a new plat­form for the on­col­o­gy pipeline. 

The Ger­man bio­phar­ma com­pa­ny has bagged Gene­va-based AMAL Ther­a­peu­tics, pay­ing out an un­spec­i­fied up­front in a $358 mil­lion deal — cash, mile­stones and every­thing else, all in. Plus there’s 100 mil­lion eu­ros on the line for com­mer­cial mile­stones.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER